Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Puma Biotechnology (PBYI) Net Margin (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Net Margin for 9 consecutive years, with 22.48% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Margin rose 72.0% year-over-year to 22.48%, compared with a TTM value of 15.43% through Dec 2025, up 524.0%, and an annual FY2024 reading of 10.46%, up 1092.0% over the prior year.
  • Net Margin was 22.48% for Q4 2025 at Puma Biotechnology, up from 16.76% in the prior quarter.
  • Across five years, Net Margin topped out at 24.79% in Q3 2024 and bottomed at 96.6% in Q3 2021.
  • Average Net Margin over 5 years is 1.0%, with a median of 6.96% recorded in 2021.
  • The sharpest move saw Net Margin tumbled -3461bps in 2021, then soared 9589bps in 2022.
  • Year by year, Net Margin stood at 7.45% in 2021, then grew by 11bps to 8.28% in 2022, then plummeted by -274bps to 14.42% in 2023, then skyrocketed by 251bps to 21.77% in 2024, then grew by 3bps to 22.48% in 2025.
  • Business Quant data shows Net Margin for PBYI at 22.48% in Q4 2025, 16.76% in Q3 2025, and 11.76% in Q2 2025.